Ramjeet Mahendrasingh, Deslandes Vincent, Gouré Julien, Jacques Mario
Groupe de recherche sur les maladies infectieuses du porc, Faculté de médecine vétérinaire, Université de Montréal, C.P. 5000, Saint-Hyacinthe, QC, J2S 7C6, Canada.
Anim Health Res Rev. 2008 Jun;9(1):25-45. doi: 10.1017/S1466252307001338. Epub 2008 Mar 17.
With the growing emergence of antibiotic resistance and rising consumer demands concerning food safety, vaccination to prevent bacterial infections is of increasing relevance. Actinobacillus pleuropneumoniae is the etiological agent of porcine pleuropneumonia, a respiratory disease leading to severe economic losses in the swine industry. Despite all the research and trials that were performed with A. pleuropneumoniae vaccination in the past, a safe vaccine that offers complete protection against all serotypes has yet not reached the market. However, recent advances made in the identification of new potential vaccine candidates and in the targeting of specific immune responses, give encouraging vaccination perspectives. Here, we review past and current knowledge on A. pleuropneumoniae vaccines as well as the newly available genomic tools and vaccination strategies that could be useful in the design of an efficient vaccine against A. pleuropneumoniae infection.
随着抗生素耐药性的日益出现以及消费者对食品安全的需求不断增加，预防细菌感染的疫苗接种变得越来越重要。胸膜肺炎放线杆菌是猪胸膜肺炎的病原体，这是一种呼吸道疾病，给养猪业造成严重经济损失。尽管过去对胸膜肺炎放线杆菌疫苗进行了所有的研究和试验，但一种能提供针对所有血清型完全保护的安全疫苗尚未上市。然而，在鉴定新的潜在疫苗候选物和针对特定免疫反应方面取得的最新进展，为疫苗接种带来了令人鼓舞的前景。在这里，我们回顾了关于胸膜肺炎放线杆菌疫苗的过去和当前知识，以及新可用的基因组工具和疫苗接种策略，这些可能有助于设计一种有效的抗胸膜肺炎放线杆菌感染疫苗。
